Core Viewpoint - Lepu Biopharma-B (02157) has entered into a CDMO service framework agreement with Lepu Medical, aiming to utilize excess production capacity more effectively and generate supplementary cash flow for the group [1] Group 1: Agreement Details - The agreement is set to commence on November 28, 2025, and involves Lepu Biopharma and/or its subsidiaries providing CDMO technical services to Lepu Medical and/or its subsidiaries [1] - The framework agreement is designed to meet the drug production needs for clinical trials and commercialization, while also allowing the company to capitalize on suitable business opportunities [1] Group 2: Financial Implications - The board believes that entering into the CDMO service framework agreement will enable the group to better utilize its surplus capacity, thereby contributing to overall cash flow generation [1]